We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in ResMed (RMD - Free Report) ten years ago? It may not have been easy to hold on to RMD for all that time, but if you did, how much would your investment be worth today?
ResMed's Business In-Depth
With that in mind, let's take a look at ResMed's main business drivers.
ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep.
The company currently has two operating segments, which are the Sleep and Respiratory Care segment (88.2% of total revenues in fiscal 2023) and the Software-as-a-Service ("SaaS") segment (approximately 11.8% in fiscal 2023). In fiscal 2023, the first segment registered 17% revenue growth, while the latter registered 24% revenue growth from fiscal 2022.
Sleep and Respiratory Care includes Device, and Masks and other.
Devices include continuous positive airway pressure ("CPAP"), variable positive airway pressure ("VPAP") and AutoSet systems for the titration and treatment of SDB. During fiscal year 2017, AirMini, the smallest portable CPAP on the market was launched. The company also acquired a line of Chinese-developed and manufactured sleep and ventilation devices with the acquisition of Curative Medical in fiscal year 2016.
Masks and others: This portfolio consist of different masks for SDB treatments like AirFit F20 in the full-face category and the AirFit N20, AirFit N30i, AirTouch N20 etc.
SaaS: Following multiple acquisitions, including Brightree LLC in April 2016, HEALTHCARE first in July 2018 and MatrixCare in November 2018, ResMed operates the SaaS business in the United States and Germany. This includes out-of-hospital software platforms designed to support professionals and caregivers who help people stay healthy at home or in a care setting of their choice.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in ResMed a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2014 would be worth $4,355.35, or a 335.54% gain, as of May 7, 2024. Investors should keep in mind that this return excludes dividends but includes price appreciation.
The S&P 500 rose 177.38% and the price of gold increased 70.50% over the same time frame in comparison.
Looking ahead, analysts are expecting more upside for RMD.
ResMed benefits from the global supply of its cloud-connected platforms, AirSense10 and AirSense11. The strong uptake of the myAir app with Air 11 is likely to drive higher adherence to therapy in patients. The company continues to see strong growth in the U.S. mask and accessories business, where resupply programs are powered by a digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers, and myAir for patients. The MEDIFOX DAN business contributes to the robust organic growth of the SaaS business, raising optimism. We expect the company’s revenues to grow at 6.4% CAGR through fiscal 2024-2026. Meanwhile, ResMed has been witnessing pressure on margin over the past few quarters due to varied macroeconomic issues. A balance sheet with a high debt burden is worrisome.
The stock is up 15.54% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 5 higher, for fiscal 2024. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in ResMed (RMD - Free Report) ten years ago? It may not have been easy to hold on to RMD for all that time, but if you did, how much would your investment be worth today?
ResMed's Business In-Depth
With that in mind, let's take a look at ResMed's main business drivers.
ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep.
The company currently has two operating segments, which are the Sleep and Respiratory Care segment (88.2% of total revenues in fiscal 2023) and the Software-as-a-Service ("SaaS") segment (approximately 11.8% in fiscal 2023). In fiscal 2023, the first segment registered 17% revenue growth, while the latter registered 24% revenue growth from fiscal 2022.
Sleep and Respiratory Care includes Device, and Masks and other.
Devices include continuous positive airway pressure ("CPAP"), variable positive airway pressure ("VPAP") and AutoSet systems for the titration and treatment of SDB. During fiscal year 2017, AirMini, the smallest portable CPAP on the market was launched. The company also acquired a line of Chinese-developed and manufactured sleep and ventilation devices with the acquisition of Curative Medical in fiscal year 2016.
Masks and others: This portfolio consist of different masks for SDB treatments like AirFit F20 in the full-face category and the AirFit N20, AirFit N30i, AirTouch N20 etc.
SaaS: Following multiple acquisitions, including Brightree LLC in April 2016, HEALTHCARE first in July 2018 and MatrixCare in November 2018, ResMed operates the SaaS business in the United States and Germany. This includes out-of-hospital software platforms designed to support professionals and caregivers who help people stay healthy at home or in a care setting of their choice.
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in ResMed a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2014 would be worth $4,355.35, or a 335.54% gain, as of May 7, 2024. Investors should keep in mind that this return excludes dividends but includes price appreciation.
The S&P 500 rose 177.38% and the price of gold increased 70.50% over the same time frame in comparison.
Looking ahead, analysts are expecting more upside for RMD.
ResMed benefits from the global supply of its cloud-connected platforms, AirSense10 and AirSense11. The strong uptake of the myAir app with Air 11 is likely to drive higher adherence to therapy in patients. The company continues to see strong growth in the U.S. mask and accessories business, where resupply programs are powered by a digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers, and myAir for patients. The MEDIFOX DAN business contributes to the robust organic growth of the SaaS business, raising optimism. We expect the company’s revenues to grow at 6.4% CAGR through fiscal 2024-2026. Meanwhile, ResMed has been witnessing pressure on margin over the past few quarters due to varied macroeconomic issues. A balance sheet with a high debt burden is worrisome.
The stock is up 15.54% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 5 higher, for fiscal 2024. The consensus estimate has moved up as well.